Category Added in a WPeMatico Campaign
AI is blowing up music. How should the Grammys handle it? Read More »
Salesforce has signed a definitive agreement to acquire Contentful, the API-first headless content management platform used by more than 4,800 enterprises to deliver digital experiences across web, mobile, and emerging channels. The deal, announced on Sunday, does not disclose financial terms. Contentful was last valued at more than $3 billion in a 2021 Series F round […]
This story continues at The Next Web
The AI boom has created a two-speed startup economy. Companies building on generative AI are raising at historically unprecedented valuations, while startups that last raised capital before ChatGPT launched in November 2022 are watching their worth collapse. According to PitchBook valuation estimates, more than 220 companies that once held billion-dollar valuations have now fallen below that threshold, […]
This story continues at The Next Web
AI is crushing startup valuations for companies that raised before ChatGPT existed Read More »
Strava blames zero-code AI apps and scrapers as it tightens API access Read More »
There’s a widening gap between what the market says about AI and what we actually hear from customers. The media, the VCs, the AI labs, and influencers have all talked about AI replacing humans, ripping out trusted software, and token-maxxing as ends worth pursuing. But the leaders running real businesses are increasingly asking the right questions. How do I make my people better with AI? Which systems can I trust? How can I measure the ROI of this spend? We hear these questions every day.
The AI Perception Reality Gap Read More »
Xbox and PlayStation have a lot to prove Read More »
Hands-on with Baseus Bowie MC2 open earbuds: Find out how to get them for $50 Read More »
Link intent combines authoritative content with strategic outreach to build links, referral traffic, and AI search visibility.
Link intent: How to combine great content with strategic outreach Read More »
In April 2021, as India was locked down during the second wave of COVID-19, three c
From a Koramangala 2BHK to Rs 100 Cr ARR: How 3 CAs built RegisterKaro Read More »
Akeso, the Chinese biotechnology company whose drug ivonescimab was dubbed “biotech’s DeepSeek moment” last year, has reported phase three clinical trial results showing a 34% reduction in the risk of death for patients with advanced squamous non-small cell lung cancer. The data, filed with the Hong Kong stock exchange on Monday and selected for the American Society […]
This story continues at The Next Web